Table of Contents

List of Abbreviations

1-ABT	1-aminobenzotriazole
ACN	Acetonitrile
ACT	Artemisinin based combination therapy
ADME	Absorption, distribution, metabolism and elimination
AM	Absorption-Metabolism
amu	atomic Mass Unit
ATP	Adenosine triphosphate
Ahr	Aryl hydrocarbon receptor
AUC	Area under curve
AVID	Automation, Validation, Integration, Database Management
BSA	Bovine serum albumin
CAD	Collision activated dissociation
CAR	Constitutive androstane receptor
CC	Calibration Curve
CDRI	Central Drug Research Institute
CE	Collision Energy
CES	Collision Energy Spread
CID	Collision Induced Dissociation
Cl	Clearance
C_{max}	Maximum concentration
CS	Calibration standards
% C.V.	Coefficient of variation
CRO	Contract Research Organization
CYP450	Cytochrome P450
DDI	Drug Drug Interaction
DHA	Dihydroartemisinin
DMPK	Drug metabolism and pharmacokinetics
DP	Declustering Potential,
EC_{50}	concentration of substrate that gives a response half way between *Bottom* and *Top*
EMS	Enhanced mass scan

EPS	Enhanced product ion
ER	Enhanced resolution
ESI	Electro spray ionization
FAD	flavin adenine dinucleotide
FMN	Flavin mononucleotide
FMO	Flavin containing mono-oxygenases
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
GLP	Good laboratory Practice
HEPES	*4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid*)
HPLC-UV	High Performance Liquid Chromatography-UV Visible spectrophotometry
HTS	Highthroughput Screening
IAEC	Institutional Animal Ethics Committee
IC_{50}	concentration of inhibitor corresponding to a 50% decrease in reaction velocity compared to the control reaction
in vitro $t_{1/2}$	*in vitro* metabolic half life ($t_{1/2}$)
in vitro Cl_{int}	*in vitro* hepatic intrinsic clearance (Cl_{int})
IPO	Initial Public Offering
IS	Internal standard
K_m	Michaelis-Menten constant for a substrate
LC-MS	Liquid Chromatography-Mass spectrometry
LC-MS/MS	Liquid Chromatography tandem mass spectrometry
LC-NMR	Liquid Chromatography nuclear magnetic resonance
LLOQ	Lower limit of quantification
LOD	Limit of detection
m/z	mass to charge ratio
MFO	mixed function oxygenase
mRNA	messenger Ribonucleic acid
MMV	Medicines for Malaria Venture
MRM	Multiple reaction monitoring
MS	Mass Spectrometry
NAD	β-nicotinamide adenine dinucleotide

NADPH	Nicotinamide adeninine dinucleotide phosphate hydrogen, reduced form
NCE	New chemical entity
NDA	New drug application
NDE	New drug entity
NIH	National Institute of Health
PAPS	3'-phosphoadenosine 5'-phosphosulfate
PCR	Polymerase Chain Reaction
PD	Pharmacodynamics
PDB	Protein Data Bank
PDA	Photo diode array detector
*Pf*API	*P.falciparum* annual parasite incidence
*Pf*PR	*P.falciparum* rate
PK	Pharmacokinetics
POC	Proof of Concept
POP	Proof of Principle
PPP	Public Private Partnership
PT	Pharmacological testing
PPARα	Peroxisome proliferator-activated receptor alpha
PXR	Pregnane X receptor
QA	Quality assurance
QC	Quality control
qRT-PCR	Quantitative Real Time Polymerase Chain Reaction
QHS	Qing-hao-su
HQC	High quality control
LQC	Low quality control
MQC	Medium quality control
rpm	revolutions per minute
R_t	Retention time
% RSD	Percentage relative standard deviation
R&D	Research and Development
RNA	Ribonucleic acid
r	Pearson's correlation coefficient
[S]	Substrate concentration

S.D.	Standard deviation
S.E.	Standard Error
TDW	Triple distilled water
T_{max}	Time to reach C_{max}
UDPGA	Uridine diphosphate-glucuronic acid
UDP	Uridine diphosphate
UV	Ultra Violet
v_0	initial velocity
v/v	volume/volume
V_{max}	maximal initial reaction velocity
w/v	Weight /Volume

List of figures

List of Tables